Overview

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.

Phase:

Phase 2

Details

Lead Sponsor:

EpicentRx, Inc.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Etoposide
Etoposide phosphate
Gemcitabine
Irinotecan
Paclitaxel
Pemetrexed
Taxane
Vinorelbine